title: [The newly developed method of 19-OH-A as intermediate of estrone biosynthesis by GC-MS].
abstract: To study the serum levels of 19-hydroxyandrostenedione (19-OH-A), known as an obligatory intermediate of estrogen biosynthesis and considered to be one of the hypertensinogens, a method using GC-MS with application of synthesized [7,7-d2]androstenedione (A), [7,7-d2] 19-OH-A and [9,11-d2]estrone(E1) as internal standards was newly developed. Normal pregnant women and pregnant women complicated with hypertension near term were selected for the study. The levels of 19-OH-A and E1 increased significantly as gestation progressed [19-OH-A; 224.7 +/- 72.1 (1st trimester), 655.5 +/- 325.4 (2nd trimester). 1517.8 +/- 543.6 (3rd trimester)pg/ml], and a positive correlation was found between the levels of the two steroids. No apparent change was observed in A levels during the course of pregnancy. The mean levels of 19-OH-A in pregnancy complicated with hypertension at 2nd and 3rd trimester were 761.7 +/- 348.9 and 1473.0 +/- 491.4 pg/ml, which were compatible with those in normal pregnancy. The levels of 19-OH-A at delivery in maternal vein (MV) were 1735.1 +/- 683.9 pg/ml. Significantly higher levels of 19-OH-A were found in umbilical vein (UV) (1977.2 +/- 564.9 pg/ml) than those in umbilical artery (109.7 +/- 49.1 pg/ml). 19-OH-A concentration in term placental tissue was 16.3 ng/g.w.w. tissue. This is the first report to demonstrate the serum 19-OH-A levels measured by GC-MS and also to demonstrate the levels in the cord blood. The results indicate that 19-OH-A may be the product of pregnancy and may be derived from the feto-placental compartment.
authors: Department of Obstetrics & Gynecology, School of Medicine Showa University, Tokyo.
authors: S
authors: S
authors: Ohigashi
authors: T
authors: T
authors: Kosaki
authors: M
authors: M
authors: Hashino
authors: T
authors: T
authors: Yanaihara
authors: T
authors: T
authors: Nakayama
authors: S
authors: S
authors: Onishi
authors: Y
authors: Y
authors: Osawa
mesh_terms: D000735:Androstenedione / Q000031:analogs & derivatives* / Q000032:analysis / Q000097:blood; D055598:Chemical Phenomena; D002621:Chemistry; D004970:Estrone / Q000096:biosynthesis* / Q000097:blood; D005260:Female; D005312:Fetal Blood / Q000032:analysis*; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006801:Humans; D006973:Hypertension / Q000097:blood; D007743:Labor, Obstetric / Q000097:blood; D010920:Placenta / Q000032:analysis; D011247:Pregnancy / Q000097:blood*; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood
chemical_list: D004970:Estrone; D000735:Androstenedione; C011482:19-hydroxy-4-androstene-3,17-dione